- Home
- BIIB vs INVH Comparison
BIIB vs INVH Comparison
Compare BIIB & INVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- INVH
- Stock Information
- Founded
- BIIB 1978
- INVH 2012
- Country
- BIIB United States
- INVH United States
- Employees
- BIIB N/A
- INVH N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- INVH Real Estate
- Sector
- BIIB Health Care
- INVH Finance
- Exchange
- BIIB Nasdaq
- INVH Nasdaq
- Market Cap
- BIIB 18.7B
- INVH 18.1B
- IPO Year
- BIIB 1991
- INVH 2017
- Fundamental
- Price
- BIIB $159.15
- INVH $28.56
- Analyst Decision
- BIIB Buy
- INVH Buy
- Analyst Count
- BIIB 24
- INVH 15
- Target Price
- BIIB $174.62
- INVH $35.50
- AVG Volume (30 Days)
- BIIB 1.6M
- INVH 4.7M
- Earning Date
- BIIB 10-30-2025
- INVH 10-29-2025
- Dividend Yield
- BIIB N/A
- INVH 4.05%
- EPS Growth
- BIIB N/A
- INVH 32.35
- EPS
- BIIB 10.97
- INVH 0.95
- Revenue
- BIIB $10,065,900,000.00
- INVH $2,689,621,000.00
- Revenue This Year
- BIIB $2.97
- INVH $5.73
- Revenue Next Year
- BIIB N/A
- INVH $3.43
- P/E Ratio
- BIIB $14.52
- INVH $30.15
- Revenue Growth
- BIIB 4.77
- INVH 5.29
- 52 Week Low
- BIIB $110.04
- INVH $27.38
- 52 Week High
- BIIB $175.86
- INVH $35.80
- Technical
- Relative Strength Index (RSI)
- BIIB 66.32
- INVH 50.76
- Support Level
- BIIB $151.83
- INVH $27.69
- Resistance Level
- BIIB $157.79
- INVH $28.86
- Average True Range (ATR)
- BIIB 4.88
- INVH 0.55
- MACD
- BIIB 0.68
- INVH 0.04
- Stochastic Oscillator
- BIIB 99.65
- INVH 71.69
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 17 target markets that feature high employment and household formation growth with over 70% of the portfolio in the Western US and Florida; 15 of the 17 markets featuring average rents lower than homeownership costs.